Skip to main content

Table 4 Estimated odds of serious infection for selecteda treatment strategies of interest

From: Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis

Treatment strategy Comparator Odds ratio Standard error 95% Confidence interval
Azathioprine/6MP Methotrexate 2.75 1.42 0.17 44.07
Prednisone Azathioprine/6MP 1.34 0.76 0.30 5.96
Infliximab + azathioprine/6MP Azathioprine/6MP 0.77 0.50 0.29 2.06
Ustekinumab Natalizumab 0.51 0.63 0.15 1.73
Vedolizumab Natalizumab 0.95 0.55 0.32 2.76
Golimumab Natalizumab 2.15 0.77 0.47 9.82
Vedolizumab Ustekinumab 1.87 0.61 0.56 6.22
Golimumab Ustekinumab 4.24 0.82 0.84 21.32
Golimumab Vedolizumab 2.27 0.76 0.51 10.16
  1. Abbreviations: 6MP 6-mercaptopurine
  2. aOther group comparisons can be found in Additional files 1, 2, 3, 4, 5, 6, and 7
\